Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response
- PMID: 16980981
- DOI: 10.1038/ni1386
Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response
Abstract
At mammalian body temperature, the plague bacillus Yersinia pestis synthesizes lipopolysaccharide (LPS)-lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity. To address the effect of weak TLR4 stimulation on virulence, we modified Y. pestis to produce a potent TLR4-stimulating LPS. Modified Y. pestis was completely avirulent after subcutaneous infection even at high challenge doses. Resistance to disease required TLR4, the adaptor protein MyD88 and coreceptor MD-2 and was considerably enhanced by CD14 and the adaptor Mal. Both innate and adaptive responses were required for sterilizing immunity against the modified strain, and convalescent mice were protected from both subcutaneous and respiratory challenge with wild-type Y. pestis. Despite the presence of other established immune evasion mechanisms, the modified Y. pestis was unable to cause systemic disease, demonstrating that the ability to evade the LPS-induced inflammatory response is critical for Y. pestis virulence. Evading TLR4 activation by lipid A alteration may contribute to the virulence of various Gram-negative bacteria.
Comment in
-
Deadly plague versus mild-mannered TLR4.Nat Immunol. 2006 Oct;7(10):1017-9. doi: 10.1038/ni1006-1017. Nat Immunol. 2006. PMID: 16985495 No abstract available.
Similar articles
-
A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.Vaccine. 2007 Nov 1;25(44):7620-8. doi: 10.1016/j.vaccine.2007.08.055. Epub 2007 Sep 14. Vaccine. 2007. PMID: 17913308
-
A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.Vaccine. 2011 Apr 5;29(16):2986-98. doi: 10.1016/j.vaccine.2011.01.099. Epub 2011 Feb 12. Vaccine. 2011. PMID: 21320544 Free PMC article.
-
Deadly plague versus mild-mannered TLR4.Nat Immunol. 2006 Oct;7(10):1017-9. doi: 10.1038/ni1006-1017. Nat Immunol. 2006. PMID: 16985495 No abstract available.
-
Live-attenuated Yersinia pestis vaccines.Expert Rev Vaccines. 2013 Jun;12(6):677-86. doi: 10.1586/erv.13.42. Expert Rev Vaccines. 2013. PMID: 23750796 Review.
-
Structural features and structural variability of the lipopolysaccharide of Yersinia pestis, the cause of plague.J Endotoxin Res. 2006;12(1):3-9. doi: 10.1179/096805105X67283. J Endotoxin Res. 2006. PMID: 16420739 Review.
Cited by
-
Pathogenicity and virulence of Yersinia.Virulence. 2024 Dec;15(1):2316439. doi: 10.1080/21505594.2024.2316439. Epub 2024 Feb 22. Virulence. 2024. PMID: 38389313 Free PMC article. Review.
-
Comparison of Yersinia enterocolitica DNA Methylation at Ambient and Host Temperatures.Epigenomes. 2023 Nov 30;7(4):30. doi: 10.3390/epigenomes7040030. Epigenomes. 2023. PMID: 38131902 Free PMC article.
-
Yersinia pestis and Plague: some knowns and unknowns.Zoonoses (Burlingt). 2023;3(1):5. doi: 10.15212/zoonoses-2022-0040. Epub 2023 Jan 19. Zoonoses (Burlingt). 2023. PMID: 37602146 Free PMC article.
-
Arcobacteraceae comparative genome analysis demonstrates genome heterogeneity and reduction in species isolated from animals and associated with human illness.Heliyon. 2023 Jun 27;9(7):e17652. doi: 10.1016/j.heliyon.2023.e17652. eCollection 2023 Jul. Heliyon. 2023. PMID: 37449094 Free PMC article.
-
Peptide MSI-1 inhibited MCR-1 and regulated outer membrane vesicles to combat immune evasion of Escherichia coli.Microb Biotechnol. 2023 Sep;16(9):1755-1773. doi: 10.1111/1751-7915.14297. Epub 2023 Jun 16. Microb Biotechnol. 2023. PMID: 37329166 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials